Clinical trial
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial…
NCT00280995 · Kastle Therapeutics, LLC, Industry · Completed
Key facts
| NCT number | NCT00280995 |
|---|---|
| Title | Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy |
| Official title | A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects |
| Lead sponsor | Kastle Therapeutics, LLC, Industry |
| Collaborators | Ionis Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia, Familial |
| Intervention type | Drug |
| Interventions | ISIS 301012 |
| Enrollment | 12 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 24, 2006 |
| Last update posted | Aug 3, 2016 |
| Countries | Netherlands, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: